Table 5. Results of specificity of immunohistochemistry based neutralization test.
Sample # | Pretreatment conditions | Observed titer (IU/mL) |
Fold change in titer (IU/mL)§* |
|
---|---|---|---|---|
142/11 | Homologous Competitor (Inactivated Rabies Pitman Moore Strain) | 1:2 Diluted Media Control |
8.9 | N/A |
1:2 Diluted Competitor |
<0.1 | (–) 178.0 | ||
1:4 Diluted Competitor |
0.5 | (–) 17.8 | ||
1:8 Diluted Competitor |
2.0 | (–) 4.5 | ||
Heterologous Competitor (Inactivated Measles Virus) | 1:2 Diluted Media Control |
10.0 | N/A | |
1:2 Diluted Competitor |
10.3 | (+) 1.3 | ||
1:4 Diluted Competitor |
11.4 | (+) 1.4 | ||
1:8 Diluted Competitor |
8.9 | (–) 1.1 |
HRIG was treated with either increasing concentrations of rabies vaccine or inactivated measles virus and RVNA titers tested. There is a marked decrease in titers after treating with homologous inhibitor compared with heterologous inhibitor.